NCT06995820View on ClinicalTrials.gov

A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.

PHASE1RecruitingINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

June 6, 2025

Primary Completion Date

October 12, 2026

Study Completion Date

October 12, 2026

Conditions
Healthy
Interventions
DRUG

AZD1613

AZD1613 will be administered as either SC injection or IV infusion on Day 1 in Part A and on Days 1, 29 and 57 in Part B of the study.

DRUG

Placebo

Placebo will be administered as either SC injection or IV infusion on Day 1 in Part A and Days 1, 29 and 57 in Part B fo the study.

Trial Locations (1)

91206

RECRUITING

Research Site, Glendale

Sponsors

Lead Sponsor

AstraZeneca

Collaborators (1)

Parexel
All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

AstraZeneca

INDUSTRY